Apogee Therapeutics DEF 14A: Executive Compensation Details
Ticker: APGE · Form: DEF 14A · Filed: Apr 29, 2025 · CIK: 1974640
| Field | Detail |
|---|---|
| Company | Apogee Therapeutics, Inc. (APGE) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
TL;DR
Apogee's 2025 DEF 14A drops, showing exec comp details & equity awards for 2023. Payouts look standard.
AI Summary
Apogee Therapeutics, Inc. filed a DEF 14A on April 29, 2025, detailing executive compensation for the fiscal year ending December 31, 2023. The filing includes information on equity awards granted, outstanding and unvested awards, and changes in the fair value of these awards for both principal executive officers (PEO) and non-principal executive officers (Non-PEO). Specific individuals like Jane Pritchett Henderson and Carl Dambkowski, MD, are mentioned in relation to equity awards.
Why It Matters
This filing provides transparency into how Apogee Therapeutics compensates its top executives, which can influence investor perception and the company's ability to attract and retain talent.
Risk Assessment
Risk Level: low — This is a routine proxy statement detailing executive compensation and is not indicative of immediate financial risk.
Key Numbers
- 2023 — Fiscal Year End (The primary year for compensation data reported in the filing.)
- 20250429 — Filing Date (The date Apogee Therapeutics filed this DEF 14A.)
Key Players & Entities
- Apogee Therapeutics, Inc. (company) — Filer of the DEF 14A
- Jane Pritchett Henderson (person) — Executive mentioned in relation to equity awards
- Carl Dambkowski, MD (person) — Executive mentioned in relation to equity awards
- 0000950170-25-060147 (dollar_amount) — Accession Number for the filing
FAQ
What is the total value of equity awards granted to PEOs in 2023?
The filing indicates that for the fiscal year 2023, there were equity awards granted to PEO members, but the specific total dollar amount is not provided in this excerpt.
What was the change in fair value of outstanding and unvested equity awards for Non-PEO members in 2024?
The filing references 'ecd:NonPeoNeoMember ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember 2024-01-01 2024-12-31', indicating a change in fair value for these awards during 2024, though the specific value is not detailed in this snippet.
When did Apogee Therapeutics change its name from Apogee Therapeutics, LLC?
Apogee Therapeutics, Inc. was formerly known as Apogee Therapeutics, LLC, and the date of the name change was April 20, 2023.
Who are the named executives related to equity award data?
The filing specifically mentions Jane Pritchett Henderson and Carl Dambkowski, MD, in relation to equity awards and their fair values as of specific dates in 2024.
What is the SIC code for Apogee Therapeutics, Inc.?
Apogee Therapeutics, Inc. has a Standard Industrial Classification (SIC) code of 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 by Jane Pritchett Henderson regarding Apogee Therapeutics, Inc. (APGE).